Vera Therapeutics, Inc. · 10 hours ago
Associate Director, CMC Technical Writer
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. They are seeking an experienced technical writer to author and review technical and regulatory documents for the chemistry, manufacturing, and controls (CMC) function, collaborating closely with various teams to ensure complete and accurate documentation.
BiotechnologyHealth Care
Responsibilities
Author and review internal documents including protocols, reports, SOPs, deviations, change controls, and manuscripts in support of all CMC functions
Work closely with the members of the CMC and Regulatory functions to author and review regulatory documents including IND/IMPD/BLA/MAA sections and meeting packages
Collaborate with CMC, Quality, and Regulatory colleagues to develop story boards for inspections and responses to information requests
Review external documents from Vera’s supply chain network
Develop document templates and workflows for technical documents
Qualification
Required
MS in Chemistry, Biochemistry, or related discipline with a minimum of 6+ years or BS in Chemistry, Biochemistry, or related discipline with a minimum of 8+ years of experience in clinical-stage biopharma with a proven technical track record in technical writing supporting CMC for Biologics
Experience authoring and reviewing a diverse set of technical documents including technical reports, manuscripts, regulatory filings including BLA/MAA across a broad technical background (analytical, process development, manufacturing)
Experience working with contract service providers is a plus
Effective communication and documentation skills
Strong attention to detail and organization
Excellent interpersonal skills and demonstrated ability to work well in a team-oriented environment
Candidates must be authorized to work in the U.S
Company
Vera Therapeutics, Inc.
Vera Therapeutics, Inc.
Funding
Current Stage
Public CompanyTotal Funding
$1.23BKey Investors
Oxford Finance LLCAbingworth
2025-12-09Post Ipo Equity· $261M
2025-06-03Post Ipo Debt· $75M
2024-10-28Post Ipo Equity· $300M
Leadership Team
Recent News
bloomberglaw.com
2025-12-20
2025-12-10
2025-12-10
Company data provided by crunchbase